v3 Template
C

Constantiam Biosciences

Biotechnology / Genomic Medicine ~260 employees
Founded
--
Employees (Est.)
~260
13 leaders known
Total Funding
$2.0M
Funding Rounds
1
Last Funding
2024-09-04

About Constantiam Biosciences

Constantiam Biosciences is dedicated to accelerating the development of life-saving precision diagnostics and therapeutics by elucidating the consequences of human genetic variation.

Products & Services

RareScan:Uses Deep Mutational Scanning (DMS) to classify variants of uncertain significance (VUS) and predict drug responses, improving patient access to treatments and aiding drug development for rare diseases.
Genable:Revolutionizes drug target discovery by integrating human genetic data, massively-multiplexed experiments, and machine learning to prioritize high-confidence targets, accelerating discovery and reducing costs.
StratiVar:Optimizes clinical trial enrollment by assessing susceptibility of protein variations to novel therapeutics using drug-specific Deep Mutational Scans (DMS), providing actionable insights on drug-sensitivity and patient response probabilities.
MAVEvidence:A premier functional evidence resource for clinical genetics, offering comprehensive curation and analysis of high-throughput studies of genetic variants to increase productivity and save time.

Specialties

Massively multiplexed functional genomics experiments Human biobank data integration Probabilistic machine learning Deep Mutational Scanning (DMS) Precision diagnostics and therapeutics

Funding History

Debug: View Raw Funding Data
# Type Amount Fields Date Fields Investors
1 RT: Phase II SBIR Grant
T: -
FT: Phase II SBIR Grant
A: 2050000
MR: -
FA: $2.05 million
FAN: 2050000
D: 2024-09-04
FD: 2024-09-04
1 investors
Phase II SBIR Grant Latest
2024-09-04
$2.0M
1 investor (Pro only)

Growth Metrics

+45%
Employee Growth
YoY
3.2x
Funding Growth
Last Round
12
Markets
Operating
10K+
Customers
Active

View 3 more growth metrics with Pro

Unlock All Metrics
Mock Up

Team & Leadership

N

Nicholas Schafer

Co-Founder and CEO

LinkedIn (Pro only)
D

Daniel Goldman

Co-Founder and CSO

LinkedIn (Pro only)
N

Norman Ong

Co-Founder and Chief Commercial Officer

N

Nicole Persky

Director, Functional Genomics

Z

Zainab Waseem

Marketing and Comms Strategist

F

Frederick Roth

Founding Scientific Advisor

View 10 more team members with Pro

Unlock Full Team Directory

Recent News

Constantiam Biosciences Announces New Product Launch

2 days ago

Company unveils innovative solution to transform the industry, expanding market reach and capabilities...

Read more →

Leadership Team Expands with Industry Veteran

1 week ago

New executive brings 20+ years of experience to accelerate growth and strategic initiatives...

Read more →

Company Recognized as Industry Leader

2 weeks ago

Receives prestigious award for innovation and customer satisfaction in competitive market...

Read more →

View 2 more news articles with Pro

Unlock Full News Feed
Mock Up

Key Competitors

C1

Competitor Alpha

Series B · $50M raised

C2

Competitor Beta

Series C · $120M raised

C3

Competitor Gamma

Series A · $25M raised

C4

Competitor Delta

Seed · $10M raised

Mock Up

Company Details

Industries
Biotechnology / Genomic Medicine
Company Size
~260 employees (est.)

Technology Stack

Discover the backend, frontend, and infrastructure technologies powering this company's products.

Upgrade to Pro